Retroviral Recombination, RNA Dimers & Multiple Drug Resistant HIV-1
Funder
National Health and Medical Research Council
Funding Amount
$405,017.00
Summary
The emergence of multiple drug resistant strains of HIV-1 has threatened the continue success of current clinical treatment to suppress virus propagation. Retroviruses, such as HIV-1, can reshuffle its two copies of genetic materials during the viral replication process, which leads to the production of offspring viruses that contain a mixture of the parental genetic materials. This process of genetic information reshuffling is believed to be important for the generation of multiple drug resista ....The emergence of multiple drug resistant strains of HIV-1 has threatened the continue success of current clinical treatment to suppress virus propagation. Retroviruses, such as HIV-1, can reshuffle its two copies of genetic materials during the viral replication process, which leads to the production of offspring viruses that contain a mixture of the parental genetic materials. This process of genetic information reshuffling is believed to be important for the generation of multiple drug resistant strains of HIV-1. The objective of this proposal is to define the parameters that regulate the reshuffling of HIV-1 genetic materials and to design novel tools to inhibit the production of multiple drug resistant HIV-1.Read moreRead less
Current combination antiviral therapy can't cure an HIV infection because long-lived T-cells carrying latent HIV DNA can rekindle the infection when drugs are removed. We will study elements in HIV genetic code that control expression of HIV proteins from latent HIV. A detailed molecular understanding of the structure and function of these HIV RNA elements and the viral and host cell factors that interact with them will expose new targets for therapy of latent HIV.
Both human and viral genetic materials (ribonucleic acids, RNA) are made up of 4 different basic residues, namely A, U, G and C. Combination of any three of these ribonucleic acids residues is known as codon , which is essential to target one of the twenty amino acids to the host cell machinery for the making of proteins. Eighteen out of these twenty amino acids can be represented by more than one codon during the making of proteins. Interestingly, human and viral proteins, such as HIV-1, utilis ....Both human and viral genetic materials (ribonucleic acids, RNA) are made up of 4 different basic residues, namely A, U, G and C. Combination of any three of these ribonucleic acids residues is known as codon , which is essential to target one of the twenty amino acids to the host cell machinery for the making of proteins. Eighteen out of these twenty amino acids can be represented by more than one codon during the making of proteins. Interestingly, human and viral proteins, such as HIV-1, utilise two completely different subsets of codons (codon bias) for the synthesis of their respective proteins. The objective of this proposal is to delineate the functional requirement of this codon bias in HIV-1 replication cycle. Results from this work will identify novel elements that may be used for the design of novel antiretroviral strategy. Furthermore, lesson learned from this project will also provide important clues to improve the efficacy and safety of the design of current retroviral gene delivery vector.Read moreRead less
Control Of Viral Replication By Non-coding Viral RNA
Funder
National Health and Medical Research Council
Funding Amount
$502,270.00
Summary
In 25 years since identified, HIV-AIDS deaths have exceeded 30 million and 40 million more are now living with HIV. The toll will soon far surpass any other infectious disease epidemic in history, or even military deaths from war in the past century. While effective combination drug therapies are available, multi-drug resistant HIV strains are commonly transmitted, leaving some patients with limited treatment options. New classes of drugs aimed at different steps in virus replication are urgentl ....In 25 years since identified, HIV-AIDS deaths have exceeded 30 million and 40 million more are now living with HIV. The toll will soon far surpass any other infectious disease epidemic in history, or even military deaths from war in the past century. While effective combination drug therapies are available, multi-drug resistant HIV strains are commonly transmitted, leaving some patients with limited treatment options. New classes of drugs aimed at different steps in virus replication are urgently needed. We have discovered that viral RNAs that do not code for protein serve important functions in HIV replication. We will study the molecular mechanisms these non-coding (intron) RNAs previously considered junk use to support of HIV gene expression and assess their potential as drug targets. First, we will investigate the role of these junk RNA loops, or lariat introns, produced in large amounts during the HIV replication cycle. Retroviruses employ RNA splicing to make mRNA for envelope and regulatory accessory genes. The complex alternative RNA splicing pattern of HIV spawns several non-coding lariats, including the lariat-intron that contains much of the removed env coding sequence. We have made the counterintuitive finding that the env-lariat dramatically enhances expression of Env protein. We will examine how this occurs and the involvement of the new class of gene-expression controlling micro-RNAs in this process. We will test for functional activity from the other lariat-introns that are produced by HIV. Second, we will characterise the mRNA-element required for efficient expression of the HIV envelope glycoprotein, Env gp160, which is essential for virus binding and entry during infection. This RNA-element directs the cell protein translation machinery to commence protein synthesis at the start of the Envgp160 rather than at upstream start sites for Vpu and Rev. We will determine how this RNA element works, its structure, and how it might be inactivated.Read moreRead less